Cover Image

CELESTIA: Cost-Effectiveness Analysis of Empagliflozin Versus Sitagliptin in Patients with Type 2 Diabetes in Greece

Gianni Ghetti,1 Lorenzo Pradelli,1 Giannis Papageorgiou,2 George Karpouzos,2 Yelda Arikan3 1AdRes Health Economics and Outcome Research, Turin, Italy; 2Boehringer Ingelheim Hellas, Athens, Greece; 3Boehringer Ingelheim, Amsterdam, the NetherlandsCorrespondence: Gianni Ghetti, AdRes Health Economics...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ghetti G (Author), Pradelli L (Author), Papageorgiou G (Author), Karpouzos G (Author), Arikan Y (Author)
Format:	Book
Published:	Dove Medical Press, 2023-02-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comparative study on efficacy of empagliflozin versus sitagliptin, as an add-on therapy to metformin in type 2 diabetic patients
by: Harsh Salankar, et al.
Published: (2024)

Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in Italy
by: Lorenzoni V, et al.
Published: (2017)

Preliminary Cost-Effectiveness and Cost-Utility Analysis of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma in Italy
by: Ghetti G, et al.
Published: (2021)

Cost–benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand
by: Deerochanawong C, et al.
Published: (2019)

Evaluation of Metformin + Sitagliptin versus Metformin + Glibenclamide on Glycemic Control in Iraqis Type 2 Diabetic Patients
by: Hassan M. Al-Temimi, et al.
Published: (2017)

Evaluation of Metformin + Sitagliptin versus Metformin + Glibenclamide on Glycemic Control in Iraqis Type 2 Diabetic Patients
by: Hassan M. Al-Temimi, et al.
Published: (2017)

Empagliflozin in the treatment of type 2 diabetes: evidence to date
by: Shubrook JH, et al.
Published: (2015)

The role of empagliflozin in the management of type 2 diabetes by patient profile
by: Hedrington MS, et al.
Published: (2015)

Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes
by: Munir KM, et al.
Published: (2016)

Clinical outcomes and health care costs combining metformin with sitagliptin or sulphonylureas or thiazolidinediones in uncontrolled type 2 diabetes patients
by: Degli Esposti L, et al.
Published: (2014)

Cost-effectiveness of Empagliflozin Compared to Liraglutide in Iran Based on Cardiovascular Outcome Trials in Type 2 Diabetes Mellitus
by: Nayyereh Ayati, et al.
Published: (2022)

Empagliflozin's role in early tubular protection for type 2 diabetes patients
by: Chuangbiao Zhang, et al.
Published: (2024)

Sitagliptin Prevents Inflammation and Apoptotic Cell Death in the Kidney of Type 2 Diabetic Animals
by: Catarina Marques, et al.
Published: (2014)

Efficacy and Safety of Empagliflozin as Add-On Therapy in Patients of Type-2 Diabetes Mellitus
by: Nauman Wazir, et al.
Published: (2022)

Evaluating Impact of Empagliflozin on Lipid Profile of Patients of Type 2 Diabetes Mellitus
by: Nauman Wazir, et al.
Published: (2022)

Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin
by: Andrew Ahmann
Published: (2015)

Sitagliptin and Fractures in Type 2 Diabetes: A Nationwide Population-Based Propensity-Matching Study
by: Shih-Yi Lin, et al.
Published: (2018)

Factors Correlated to the Renoprotective Effect of Sitagliptin in Patients with Type 2 Diabetes Mellitus: Retrospective Observational Study
by: Pirawan Khunkit, et al.
Published: (2024)

Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes
by: Giampietro O, et al.
Published: (2013)

Effect of Empagliflozin On Liver Enzymes of Patients In Non-Alcoholic Steatohepatitis In Type 2 Diabetes Mellitus
by: Nauman Wazir, et al.
Published: (2023)

Does Empagliflozin Modulate Leukocyte-Endothelium Interactions, Oxidative Stress, and Inflammation in Type 2 Diabetes?
by: Francisco Canet, et al.
Published: (2021)

Influence of Adding Empagliflozin to Conventional Anti-diabetic Therapy on Quality of Life Scale for Type 2 Diabetic Patients
by: Hadeel Delman Najim, et al.
Published: (2024)

Effects of metformin+sitagliptin versus metformin + glibenclamide combinations on lipid profile, body mass index and kidney function in Iraqi patients with type 2 diabetes mellitus.
by: Hassan Mohammed Abbas Al-Temimi, et al.
Published: (2013)

Risk of diarrhea in patients with type 2 diabetes mellitus treated with sitagliptin: a meta-analysis of 30 randomized clinical trials
by: Zhao QW, et al.
Published: (2014)

Dapagliflozin versus empagliflozin in patients with chronic kidney disease
by: Hilmi Alnsasra, et al.
Published: (2023)

Development and optimization of sitagliptin and dapagliflozin loaded oral self-nanoemulsifying formulation against type 2 diabetes mellitus
by: Mohsin Kazi, et al.
Published: (2021)

Chitosan oligosaccharide improves the therapeutic efficacy of sitagliptin for the therapy of Chinese elderly patients with type 2 diabetes mellitus
by: Zhao L, et al.
Published: (2017)

Potential Therapeutic Benefits of Metformin Alone and in Combination with Sitagliptin in the Management of Type 2 Diabetes Patients with COVID-19
by: Hayder M. Al-Kuraishy, et al.
Published: (2022)

A High Level of Circulating Valine Is a Biomarker for Type 2 Diabetes and Associated with the Hypoglycemic Effect of Sitagliptin
by: Xiaoyu Liao, et al.
Published: (2019)

Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat)
by: Liliana Ferreira, et al.
Published: (2010)

Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
by: Joshua J Neumiller
Published: (2014)

Sitagliptin on carotid intima-media thickness in type 2 diabetes and hyperuricemia patients: a subgroup analysis of the PROLOGUE study
by: Yipin Zhao, et al.
Published: (2021)

Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy
by: Hayes J, et al.
Published: (2016)

The effect of sitagliptin on cardiovascular risk profile in Korean patients with type 2 diabetes mellitus: a retrospective cohort study
by: Shin S, et al.
Published: (2016)

Pharmacometrics enhanced Bayesian borrowing approach to improve clinical trial efficiency: Case of empagliflozin in type 2 diabetes
by: Lucie Fayette, et al.
Published: (2023)

Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland
by: Hallinen T, et al.
Published: (2023)

Comparative Safety Analysis of Empagliflozin in Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease versus Normal Kidney Function: A Nationwide Cohort Study in Korea
by: Ha Young Jang, et al.
Published: (2023)

Assessment of Factors Affecting Therapeutic Response of the DPP-4 Inhibitor Sitagliptin in A Sample of Iraqi Type 2 Diabetic Patients
by: Ahmad Nazar Jawad, et al.
Published: (2024)

Sitagliptin on Carotid Intima-Media Thickness in Type 2 Diabetes Mellitus Patients and Anemia: A Subgroup Analysis of the PROLOGUE Study
by: Zhengri Lu, et al.
Published: (2020)

Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study
by: Imtiyaz Ahmed Najar, et al.
Published: (2022)